The global respiratory syncytial virus (RSV) vaccine market is on a steep growth trajectory, driven by increasing awareness of RSV’s health impact, technological advancements in vaccine development, and rising hospitalization rates among infants and the elderly. Valued at US$ 3.7 billion in 2024, the market is projected to grow at an impressive CAGR of 13.8% from 2025 to 2035, surpass... https://www.transparencymarketresearch.com/respiratory-syncytial-virus-vaccine-market.html